For Immediate Release: July 29, 2015
Upcoming Live Webinar Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Operations
CINCINNATI, OH — (July 29, 2015) – Medpace experts will be presenting a live webinar titled: Pharmacoeconomic Assessment through Market Approval and Beyond: Theory and Operations.
DATE: Wednesday, August 26
TIME: 11:30am ET / 8:30am
PT DURATION: 1 Hour
About the Webinar:
Pharmacoeconomic assessment of a drug, medical device, or other healthcare product can take on many forms and occur at multiple points in the development cycle. Cost-effectiveness analysis, a major component of pharmacoeconomic assessment, has traditionally occurred in the later phases of product development— either as a piggy-back to a phase III or pivotal clinical trial, or peri-authorization.
Join Medpace experts, Lee Walke and Matthew Page, as they explore the application of pharmacoeconomic assessment throughout all phases of clinical trials as well as in observational studies, including registries and other post-marketing data collection. Discussion will cover topics including:
- How pharmacoeconomic assessment can be envisioned in the context of early phase product development, implemented, maintained to support product marketing, and used to inform future decision-making.
- Cost-effectiveness analysis at different phases in the product development cycle.
- Pharmacoeconomic assessment in the post-marketing context.
- Comparing and contrasting approaches for small/medium product developers relative to larger companies.
- Case studies on “real world” implementation
About the Presenters
Lee Walke, Vice President e-Clinical at Medpace
Lee Walke has nearly 25 years of progressive clinical development experience with expertise in collecting real-world outcomes and clinical data, data integration, endpoint derivation, electronic submissions, Electronic Health Records (EHR), and electronic Patient Reported Outcomes (ePRO).
Matthew J. Page, Ph.D., M.P.P., Epidemiologist at Medpace
Matt Page has a diverse background in academia and research including teaching college courses in epidemiology and biostatistics and working with pharmaceutical and medical device companies to implement numerous pharmacoeconomic methodologies, including cost-effectiveness analysis and budget impact modeling.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Its team of real world and late phase strategists and researchers can help demonstrate the safety, effectiveness and quality of your drug, combination product or medical device to key stakeholders. With a 20+ year history in designing and conducting clinical research across all phases of development, Medpace experts bring keen insights to RWE research and understand how to integrate the data throughout the development cycle. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2200 employees and has clinical trial experience in over 50 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.